First TIGIT Inhibitor Drug Is Expected To Enter The Market In Next 2 Years Says Kuick Research.
First TIGIT Inhibitor Drug Is Expected To Enter The Market In Next 2 Years Says Kuick Research
Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:
- Global TIGIT Inhibitor Market Dynamics
- Clinical Approaches to Target TIGIT
- Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders
- Number of TIGIT Inhibitor Drug In Trials
- TIGIT Inhibitors Trials By Phase, Company, Country, Indication
- Clinical Trials Adverse Events Scenario
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global TIGIT Inhibitor Market Future Outlook
Download Report:
In past few years, immunotherapy has gradually established as the forth pillar in the management of cancer following surgery, chemotherapy, and radiotherapy. Till now, a cocktail of immune checkpoint inhibitors have been approved by regulatory bodies which have shown high clinical benefits and improved the overall survival rates of cancer patients. However, their use is limited to a small range of cancers and is also associated with treatment related adverse events, which further limits their market.
Owing to high medical needs, the research and development activities were mainly focused on the identification of new receptors which can complement the existing immune checkpoint inhibitors and also reduce the financial toxicity. Recent research has identified TIGIT as a promising immune checkpoint target. TIGIT indirectly suppresses T-cell activation and has high expression on multiple types of immune cells including Treg cells, activated T cells, and natural killer cells. Apart from this, the receptor is generally expressed in several malignancies and is associated with advanced disease and poor survival outcomes.
The identification of novel immune checkpoint inhibitor and restless efforts by scientists has led to development of several anti-TIGIT antibodies. As of now, no TIGIT inhibitor has been approved by regulatory bodies for the management of cancer or other chronic disorders. However, the pipeline for this emerging drug class is highly congested. These novel antibodies are majorly present in in phase-I/II clinical trials. Recently in 2021, US FDA has granted breakthrough therapy designation to Tiragolumab, developed by Roche for the management of non-small cell lung cancer. Therefore, it is expected that the novel drug will enter the market in 2022, which will provide a boost to this segment.
Several pharmaceutical companies including Acrus Biosciences, Roche, Agensus, Gilead Sciences, Beigene, Bristol Meyer Squibb, and others have developed a robust pipeline of TIGIT inhibitors which are expected to enter the market during the forecast period. The pipeline for novel TIGIT inhibitor is highly crowded and consists of several major candidates including AB154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. The promising preclinical and clinical trials results have attracted huge investment in this sector.
The trend for strategic alliances among pharmaceutical companies is increasing at rapid rates. The major key players in the market have adopted several alliances including collaboration, partnerships, and agreement with other companies for better geographical reach for distribution of the product as well as approvals to expand the indications of products. For instance, Acrus Biosciences have entered into licensing agreement with Taiho Pharmaceutical for its anti-TIGIT program in Japan and certain other territories in Asia. The increasing trends will further boost the growth of market.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366